Abeona Therapeutics Inc vs American States Water Company — how do they compare? Abeona Therapeutics Inc trades at $7.4 (market cap $421.19M), while American States Water Company trades at $87.85 (market cap $3.47B). The key difference: American States Water Company is far larger — about 8.2× Abeona Therapeutics Inc's market cap, and American States Water Company pays a 2.49% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | AWR | |
|---|---|---|
Market Cap | $421.19M | $3.47B |
Sector | Health | Utilities |
52-Week High | $7.45 | $89.28 |
52-Week Low | $4.17 | $70.10 |
Enterprise Value | $276.10M | $4.37B |
Dividend Yield | — | 2.49% |
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $7.46, up 0.13% with strong technical momentum as moving averages signal bullish sentiment. The company shows exceptional profitability with 454.86% net income margin and 70.99% ROE, though revenue remains modest at $5.82M. Recent positive developments include CMS granting NTAP status for ZEVASKYN and expanding treatment centers, while consistently beating earnings expectations.
Outlook remains positive with analyst consensus at 66.7% buy ratings, but risks include shareholder investigation and high RSI levels suggesting overbought conditions. The stock's valuation appears reasonable with P/E of 7.78, though negative operating cash flow requires monitoring as the company scales commercialization efforts.
AWR trades at $87.95, up 1.59% on the day, with a bullish technical signal from moving averages. The company reported a Q2 2026 EPS beat of $1.09 versus $0.915 expected, driven by water rate increases and revenue growth. Recent news highlights its 71-year dividend growth streak and an 8.2% dividend hike announced in July 2026. Financials show solid profitability with a 20.52% net income margin and ROE of 13.62%, though valuation ratios like P/E of 23.92 are above sector averages.
Outlook is mixed: strong dividend history and earnings growth support income investors, but elevated valuation and mixed analyst consensus (20% buy, 50% hold, 30% sell) suggest limited near-term upside. Key risks include regulatory dependence on rate approvals and potential overvaluation relative to peers.
Trailing returns across standard periods
Latest headlines on both assets
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →American States Water provides water and electric services to over one million people in the U.S. It also manages water and wastewater systems for various military bases under long-term privatization contracts.
Read more on AWR →